DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Semaglutide 2.4 mg (Wegovy). Adults with overweight (BMI ≥27) plus comorbidity, or obesity (BMI ≥30), without diabetes.
Percent change in body weight at week 68.
Mean weight loss 14.9% with semaglutide vs 2.4% with placebo. 86.4% of semaglutide patients lost ≥5% body weight vs 31.5% in placebo group.
Adults with overweight (BMI ≥27) plus comorbidity, or obesity (BMI ≥30), without diabetes.
Once-weekly subcutaneous semaglutide 2.4 mg vs placebo, both with lifestyle intervention.
Percent change in body weight at week 68.
Mean weight loss 14.9% with semaglutide vs 2.4% with placebo. 86.4% of semaglutide patients lost ≥5% body weight vs 31.5% in placebo group.
Wilding JPH et al, NEJM 2021;384:989-1002